This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): Libivirumab and Exbivirumab for injection
Description: HepeX-B is a mixture of two human monoclonal antibodies directed against different epitopes on the surface antigen of the hepatitis B virus (HBV). It is currently being evaluated for its anti-viral activity in clinical studies.
Deal Structure: In June 2004, Cubist signed an agreement with XTL Biopharmaceuticals Ltd under which XTL granted to Cubist an exclusive, worldwide license (with the right to sub-license) to commercialize HepeX-B. Cubist is responsible for completing the development and for registration and commercialization of the product worldwide. XTL will receive milestone payments and is entitled to receive royalties from net sales by Cubist, if any, generally ranging from 10% to 17%, depending on levels of net sales achieved by Cubist, subject to certain deductions based on patent protection of HepeX-B in that territory, total cost of HepeX-B development, third party license payments and indemnification obligations.
On September 20, 2005, XOMA Ltd. signed a letter agreement with Cubist to develop new processes to manufacture HepeX-B. Specifically, the letter agreement calls for XOMA to develop commercial processes for the manufacture of two monoclonal antibodies, which together make up the HepeX-B product....See full deal structure in Biomedtracker
Partners: XTL Biopharmaceuticals Ltd. XOMA Corporation
Pink Sheet Cubist creates chief medical officer
Pink Sheet Weekly Trademark Review January 1, 2013
Additional information available to subscribers only: